BiotechTube

ONO-2506

Phase 2/3Terminated
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident

Trial Timeline

Nov 1, 2002 → —

NCT ID
NCT00046761

About ONO-2506

ONO-2506 is a phase 2/3 stage product being developed by Ono Pharmaceutical for Cerebrovascular Accident. The current trial status is terminated. This product is registered under clinical trial identifier NCT00046761. Target conditions include Cerebrovascular Accident.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00046761Phase 2/3Terminated

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors
ProductCompanyStageHype Score
YM872 (zonampanel)Astellas PharmaPhase 2
52
donepezil hclEisaiPhase 3
77
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
85
AbciximabEli LillyPhase 3
77
atomoxetine + StimulantsEli LillyPre-clinical
23
ticagrelor + ASA + Placebo+ASAAstraZenecaApproved
85
ValsartanNovartisPre-clinical
23
AtorvastatinPfizerApproved
84
RivaroxabanBayerPre-clinical
20
Darolutamide (BAY1841788) + EnzalutamideBayerPhase 1
30
Botulinum toxin type A + PlaceboIpsenApproved
82
Atorvastatin 20mgBrain BiotechApproved
77
Autologous bone marrow mononuclear cell transplantationBrain BiotechPhase 1
25
Roflumilast Oral TabletBrain BiotechPhase 2
44

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77